By Simply Wall St
Publication Date: 2026-02-14 16:06:00
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Eli Lilly (NYSE:LLY) has agreed to acquire Orna Therapeutics, moving into engineered RNA medicines for autoimmune diseases and other conditions.
The company has entered a US$1b artificial intelligence drug discovery collaboration with Nvidia to support its research pipeline.
Eli Lilly is preparing for a potential launch of its oral weight loss drug orforglipron, with an FDA decision expected in the near term and pre-launch inventory already being built.
Eli Lilly, long associated with diabetes care and more recently obesity treatments, is now pushing into cell and genetic therapies through the planned Orna Therapeutics acquisition. By adding engineered RNA medicines to its toolkit, the company is aiming to broaden its reach across autoimmune and other complex diseases, while obesity and diabetes remain central to its story.
For you as an investor, the Nvidia AI partnership and orforglipron launch preparations highlight how Lilly is working to reshape its research engine and product mix at the same time. The outcomes of the Orna deal, the AI collaboration, and the upcoming FDA decision on orforglipron may be important markers to watch as the company positions itself within weight loss treatments and next generation therapies.
Stay updated on the most important news stories for Eli Lilly by adding it to your watchlist or portfolio….


